Status:
COMPLETED
Oral vs. Intravenous TXA Study Proposal: TJA
Lead Sponsor:
Rush University Medical Center
Conditions:
Blood Loss After Primary Total Joint Arthroplasty
Need for Blood Transfusion After Total Joint Arthroplasty
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, n...
Detailed Description
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, n...
Eligibility Criteria
Inclusion
- Any patient scheduled for a primary TKA or cementless THA with epidural/spinal anesthesia
Exclusion
- Allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-op use of anticoagulant therapy within five days before surgery, a history of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy, breastfeeding, major comorbidities (such as severe ischemic heart disease \[New York Heart Association Class III or IV\], previous myocardial infarction, severe pulmonary disease, renal impairment, or hepatic failure), patients who decline to participate, any patient undergoing a revision TKA, THA or BHR
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT02233101
Start Date
June 1 2014
End Date
August 1 2015
Last Update
November 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612